Article Versions Notes

Toboni MD, Lomonosova E, Bruce SF, Tankou JI, Mullen MM, Schab A, Oplt A, Noia H, Wilke D, Kuroki LM, et al. Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. Cancers. 2021; 13(23):5877. https://doi.org/10.3390/cancers13235877

Toboni, Michael D., Elena Lomonosova, Shaina F. Bruce, Jo’an I. Tankou, Mary M. Mullen, Angela Schab, Alyssa Oplt, Hollie Noia, Danny Wilke, Lindsay M. Kuroki, and et al. 2021. "Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer" Cancers 13, no. 23: 5877. https://doi.org/10.3390/cancers13235877

Toboni, M. D., Lomonosova, E., Bruce, S. F., Tankou, J. I., Mullen, M. M., Schab, A., Oplt, A., Noia, H., Wilke, D., Kuroki, L. M., Hagemann, A. R., McCourt, C. K., Thaker, P. H., Powell, M. A., Khabele, D., Mutch, D. G., & Fuh, K. C. (2021). Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. Cancers, 13(23), 5877. https://doi.org/10.3390/cancers13235877